AGN-193408 / AbbVie - LARVOL DELTA

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P1/2 | N=96 | Recruiting | Sponsor: AbbVie | Trial completion date: Aug 2027 ➔ Aug 2028 | Trial primary completion date: Aug 2027 ➔ Aug 2028

Trial completion date • Trial primary completion date • Cardiovascular • Glaucoma • Ophthalmology

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P1/2 | N=96 | Recruiting | Sponsor: AbbVie | Trial completion date: Apr 2025 ➔ Aug 2027 | Trial primary completion date: Apr 2025 ➔ Aug 2027

Trial completion date • Trial primary completion date • Cardiovascular • Glaucoma • Ophthalmology

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P1/2; N=84; Recruiting; Sponsor: Allergan; Phase classification: P2 ➔ P1/2

Clinical • Phase classification • Glaucoma • Ophthalmology

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P2; N=84; Recruiting; Sponsor: Allergan; Trial primary completion date: Apr 2024 ➔ Apr 2025

Clinical • Trial primary completion date • Glaucoma • Ophthalmology

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P2; N=84; Recruiting; Sponsor: Allergan; Phase classification: P1/2 ➔ P2

Clinical • Phase classification • Glaucoma • Ophthalmology

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P1/2; N=84; Recruiting; Sponsor: Allergan; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Glaucoma • Hypertension • Ophthalmology

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P1/2; N=84; Not yet recruiting; Sponsor: Allergan

Clinical • New P1/2 trial • Glaucoma • Hypertension • Ophthalmology